Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding
Sabin Vaccine Institute receives $35 million from BARDA with potential of up to $214 million for Medical Countermeasure Development against ...
Tag: Select Agents
Officials Declare End to Ebola Outbreak in Uganda
After 142 confirmed cases of Ebola disease and 55 deaths, officials have declared an end to Uganda's Ebola outbreak. The ...
How Prepared is Uganda for the Current Ebola Outbreak?
An outbreak of the deadly Ebola virus was announced by Uganda’s ministry of health on 21 September 2022. Uganda has ...
Stem Cell Research Gives New Clues on Ebola Virus Damage to Organs
The resulting liver cell model will be a valuable tool for future studies on Ebola virus vital organ pathology and ...
Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast
A bacteria that causes melioidosis has been found in the soil and water for the first time in the continental ...
Poxvirus Proteins Enable Early Strike on Immune Defences
Pox viruses are able to get a head start on infecting a host by delivering a package of proteins that ...
US Starts Clinical Trial for mRNA Nipah Virus Vaccine
The experimental Nipah virus vaccine (mRNA-1215) is manufactured by Moderna, Inc. and was developed in collaboration with NIAID’s Vaccine Research ...
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Bavarian Nordic's smallpox vaccine is approved for use against monkeypox by the U.S. Food and Drug Administration and Health Canada. ...
Federal Select Agent Program Clarifies Requirements for Botulinum Neurotoxin Gene Constructs
The Federal Select Agent Program, part of the Centers for Disease Control and Prevention Division of Select Agents and Toxins, ...
New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs
Scientists uncover how poxviruses form their protein scaffold from a building block called D13, which could lead to the development ...
NIAID Funding Available for Biocontainment Facility Improvements
NIAID supports Biodefense and Emerging Infectious Diseases Research Infrastructure as a key component of our mission to safely and effectively ...
NIH Awards $3M Grant to Albany Med for Plague Vaccine Development
Albany Medical College scientists have been awarded a $3 million, five-year federal grant to develop a vaccine that could protect ...
Ebola Virus Can ‘Hide Out’ in the Brain After Treatment and Cause Recurrent Infections
The Ebola virus can hide in the brains of monkeys that have recovered after medical treatment without causing symptoms and ...
Emergency Response Missions for Recovered Chemical Warfare Material
A group of seasoned U.S. Army civilians are often called to respond on short notice when suspected recovered chemical warfare ...
CARA Microbiologists Safeguard Against Biological Threat Agents
Microbiologists from the CBRNE Analytical and Remediation Activity (CARA), an all-civilian deployable asset housed within the the 20th CBRNE Command ...
Appili Awarded $10M in New Biodefense Funding for Tularemia Vaccine Candidate
DoD funding aims to advance F. tularensis biodefense vaccine candidate to IND submission Appili Therapeutics Inc. announced this week that ...
U.S. Government to Conduct Sweeping Review of Biosecurity Policy Frameworks
The Biden Administration and National Institutes of Health (NIH) officials have initiated a review of the scope and effectiveness of ...
USAMRIID Scientist Wins AMSUS Research and Development
Xiankun (Kevin) Zeng, Ph.D., a molecular biologist and principal investigator at the U.S. Army Medical Research Institute of Infectious Diseases ...
Novel Antibiotic Shows Success in Treatment of Plague and Melioidosis
Leading scientists at Defence Science and Technology Laboratory have made an exciting new discovery in the fight against some of ...
USAMRIID Study Reveals Ebola Virus Can Hide in Brain
In a groundbreaking study, scientists describe how Ebola virus, which can persist in certain areas of the body, can re-emerge ...
